Mabpharm

Mabpharm EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Mabpharm (2181.HK) as of Oct 17, 2026 is 25.71. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -580.34 — a change of -104.43% (higher).

EV/OCF

25.71

YoY

-104.43%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Mabpharm is 2025 25.71 . EV/OCF (Enterprise Value to Operating Cash Flow) of Mabpharm was 2024 -580.34 . It decreases by -104.43% higher compared to the previous year.

The Mabpharm EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-28.55 CNY
Jan 1, 2019
-9.56 CNY
Jan 1, 2020
-9.61 CNY
Jan 1, 2021
-10.73 CNY
Jan 1, 2022
-39.59 CNY
Jan 1, 2023
39.40 CNY
Jan 1, 2024
-580.34 CNY
Jan 1, 2025
25.71 CNY
The Mabpharm EV/OCF history
YEAREV/OCFYoY
25.71-104.43%
-580.34-1,572.97%
39.40-199.51%
-39.59+269.15%
-10.73+11.60%
-9.61+0.54%
-9.56-66.52%
-28.55+0.05%
-28.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mabpharm Stock analysis

What does Mabpharm do? Mabpharm Ltd is a biopharmaceutical company based in Suzhou, China. The company was founded in 2009 and specializes in the development and production of monoclonal antibodies. The business model of Mabpharm is to develop, produce, and sell high-quality biological drugs worldwide. The company works closely with customers to understand their needs and provide customized solutions. Mabpharm is divided into different divisions, each specialized in producing specific products. The main ones are oncology, immunology, cardiology, and infectious diseases. Each division offers a portfolio of products tailored to the needs of patients. In the field of oncology, Mabpharm offers a range of monoclonal antibodies that can be used to treat cancer. This includes therapies for breast cancer, gastric cancer, colorectal cancer, and lung cancer. The products have all been developed in collaboration with renowned partners worldwide and undergo rigorous clinical testing before being brought to market. Mabpharm's immunology division focuses on developing drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The products in this division have been specifically designed to regulate the immune system and suppress inflammation symptoms. The cardiology division of Mabpharm is dedicated to the development of drugs for the prevention and treatment of cardiovascular diseases. The products include antibodies for the treatment of lipid metabolism disorders and blood clots. Mabpharm's cardiovascular products also include a cholesterol-lowering medication that helps prevent heart attacks and strokes. In the infectious diseases division, Mabpharm has developed products for the treatment of hepatitis B and hepatitis C. These can reduce viral load and improve liver function. Furthermore, Mabpharm is also involved in the development of vaccines against COVID-19. Mabpharm has become a leading provider of monoclonal antibodies and biological drugs in China and internationally. The company works closely with academics and researchers to find innovative solutions and stay up to date with the latest scientific advancements. In conclusion, Mabpharm is an innovative company specializing in the research and development of biological drugs of all kinds. The company has a wide range of products that have been developed to meet the needs of patients worldwide. Mabpharm has emerged as a key player in the global market for biological drugs in recent years and is a company to watch when it comes to the future of biotechnology. Mabpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mabpharm stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Mabpharm is 25.71 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Mabpharm changed from -580.34 to 25.71, representing a -104.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Mabpharm since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Mabpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Mabpharm

All Key Metrics — Mabpharm